Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma

NCT06527495 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

HCC
Hepatocellular Carcinoma

Interventions

DRUG: Sorafenib

Sponsor

Assiut University